Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
Previous studies have demonstrated that
2025-03-01
Previous studies have demonstrated that synaptic AMPARs can differ greatly in their mobility; some rapidly and constitutively Axitinib in and out of the synaptic membrane, while others remain somewhat stable in the synaptic membrane (Luscher et al., 1999, Luthi et al., 1999). We find that mGluR- an
-
ABT-888 Recently rather than predicting categorical
2025-03-01
Recently, rather than predicting categorical variables as in classification, several studies begin to estimate continuous clinical variables from ABT-888 images. Therefore, instead of classify a subject into binary or multiple pre-determined categories or stages of the disease, regression focus on
-
br Development of lorlatinib from crizotinib to a
2025-03-01
Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes
-
Globally the total number of
2025-03-01
Globally, the total number of patients included in the meta-analysis was 1885, ranging from 40 to 442 patients per study. All eligible studies reported the association between ALDH1 expression and patients' OS [24-26, 3241], whereas nine studies evaluated the relationship between ALDH1 expression an
-
prostaglandin e Preclinical models indicate roles for
2025-03-01
Preclinical models indicate roles for adiponectin in the maintenance of hepatic lipid metabolism. Adiponectin overexpression prevents accumulation of triglycerides or the deleterious lipid metabolites diacylglycerols or ceramides [5,8]. Direct manipulation of adiponectin expression demonstrates a po
-
GSK1904529A It is worth pointing out that phenotypes of in v
2025-03-01
It is worth pointing out that phenotypes of in vivo HSP90β inhibition were not identical to those observed in rapsyn mutant mice (Gautam et al., 1995). Postsynaptically, junctional AChR clusters appeared fragmented, in addition to expected reduction in AChR intensity, in muscles injected with 17-AAG
-
A correlation analysis was performed
2025-03-01
A correlation analysis was performed to investigate a possible relationship between serum resistin levels and MG-ADL. We observed a significant relationship between serum resistin levels and MG-ADL scores in AChR-GMG-positive cases (r=0.285, p=0.032; Fig. 1C). There were also significant correlation
-
We showed that activation of
2025-02-28
We showed that activation of the ATM/ATR pathway leads to over-replication through suppression of CDK1 activity, consistent with previous findings that suppression of CDK1 activity is involved in the polyploidization of megakaryocyte and trophoblast cells [36], [37], [38], [39]. Suppression of CDK1
-
br Conclusions and future direction ER PgR breast
2025-02-28
Conclusions and future direction ER(−)/PgR(+) breast cancers have a distinct clinical course, response to treatment, and molecular features when compared to other breast cancer types, however some of them are actually technical artifacts or consequences of too high definitions of positivity. Acco
-
Several structural classes of ASK
2025-02-28
Several structural ibuprofen solubility of ASK1 inhibitors, mostly from industry but also from academia, have been identified over the last decade. In 2012, Terao et al. (Takeda) reported imidazo[1,2-α]pyridine () as a potent ASK1 inhibitor derived from structure-based drug design. GSK, Merck and
-
The presence of crown like
2025-02-28
The presence of crown-like structures and inflammatory factors in the breast of obese patients is associated with considerable changes in intracellular signaling and a profound cellular dysfunction. Secreted pro-inflammatory factors can directly promote breast carcinogenesis as they have been report
-
The first objective of the present study
2025-02-28
The first objective of the present study was to investigate the impact of ageing on arginase activity in tissues which exhibit age-related impairments in their function. The second objective was to determine whether l-arginine supplementation modulated the effect of ageing on arginase activity. The
-
cyclic adenosine monophosphate Mitochondria are key organell
2025-02-28
Mitochondria are key organelles involved in the mechanism of apoptosis (Xiong et al., 2014), and loss of ΔΨm is an important marker associated with mitochondrial dysfunction and cell death. We found that Mino induced ΔΨm impairment and nuclear fragmentation in Jurkat cyclic adenosine monophosphate
-
The finding of the apelin APJ
2025-02-28
The finding of the apelin/APJ axis represents an impressive event in cardiovascular studies. As a result of various experimental and clinical studies conducted in vivo and in vitro, it has been indicated that apelin/APJ is a crucial mediator of cardiovascular homeostasis, which takes part in the pat
-
To further address the mechanism of Didox s suppressive
2025-02-28
To further address the mechanism of Didox’s suppressive effects on mast cell activation, FceRI receptor avibactam and downstream transcription factor induction were assessed. We found that Didox had no effect on FceRI surface expression, and thus concluded that Didox effects must be occurring downs